Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
6.93
-0.09 (-1.25%)
At close: May 29, 2026, 4:00 PM EDT
6.90
-0.03 (-0.46%)
After-hours: May 29, 2026, 4:10 PM EDT
Kyntra Bio Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 163.62 | 183.45 | -47.58 | -284.23 | -293.65 | -290.02 |
Depreciation & Amortization | 0.43 | 0.75 | 2.69 | 9.93 | 10.6 | 14.81 |
Stock-Based Compensation | 4.88 | 6.58 | 25.22 | 50.77 | 65.6 | 71.16 |
Other Adjustments | -4.03 | -42.52 | -0.87 | 28.2 | 1.09 | 61.74 |
Change in Receivables | -4.21 | -2.54 | -6.74 | 3.43 | 0.77 | 25.18 |
Changes in Inventories | 2.86 | 5.36 | 22.28 | -1.7 | -11 | -14.16 |
Changes in Accounts Payable | -1.54 | -27.65 | 14.51 | -15.51 | 5.91 | 0.81 |
Changes in Accrued Expenses | -24.24 | -53.5 | -93.79 | -49.78 | 90.56 | 16.38 |
Changes in Unearned Revenue | -128.1 | -136.43 | -28.3 | -28.17 | -4.13 | 57.64 |
Changes in Other Operating Activities | 8.12 | 61.73 | -25.43 | -27.97 | -11.67 | -25.76 |
Operating Cash Flow | -21.38 | -4.77 | -138 | -315.02 | -145.93 | -82.23 |
Capital Expenditures | -0.02 | -0.04 | -0.27 | -2.52 | -3.74 | -5.19 |
Sale of Property, Plant & Equipment | - | - | 1.05 | - | 0.01 | - |
Purchases of Intangible Assets | - | - | - | - | -35 | -25 |
Purchases of Investments | -72.21 | -61.16 | -8.63 | -251.83 | -164.02 | -484.14 |
Proceeds from Sale of Investments | 14.13 | - | 133.84 | 407.35 | 291.87 | 87.36 |
Proceeds from Business Divestments | 6.35 | 96.62 | - | - | - | - |
Other Investing Activities | - | - | - | 0.66 | - | - |
Investing Cash Flow | 38.45 | 35.42 | 125.99 | 153.66 | 89.12 | -426.97 |
Long-Term Debt Issued | - | - | - | 74.08 | - | - |
Long-Term Debt Repaid | -0.01 | -75.01 | -0.04 | -0.15 | -0.14 | -5.49 |
Net Long-Term Debt Issued (Repaid) | -0.01 | -75.01 | -0.04 | 73.93 | -0.14 | -5.49 |
Issuance of Common Stock | - | - | 0.14 | 52.14 | 4.18 | 12.7 |
Repurchase of Common Stock | -0.04 | -0.07 | -0.35 | -0.24 | -5.17 | -7.37 |
Net Common Stock Issued (Repurchased) | -0.04 | -0.07 | -0.22 | 51.9 | -0.98 | 5.33 |
Other Financing Activities | - | -10.95 | - | -3.08 | 47.89 | -0.4 |
Financing Cash Flow | -85.95 | -86.03 | -0.26 | 122.75 | 46.78 | -0.56 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -0.05 | 1.08 | 0.75 | -3.4 | -5.48 | 2.6 |
Net Cash Flow | -69.2 | -54.31 | -11.51 | -42.01 | -15.52 | -507.17 |
Free Cash Flow | -21.4 | -4.81 | -138.27 | -317.54 | -149.67 | -87.42 |
FCF Margin | -287.70% | -74.72% | -466.78% | -678.46% | -106.35% | -37.15% |
Free Cash Flow Per Share | -5.29 | -1.19 | -34.55 | -81.59 | -39.98 | -23.67 |
Levered Free Cash Flow | 21.11 | -41.34 | -155.92 | -326.01 | -217.26 | -250.99 |
Unlevered Free Cash Flow | -187.36 | -195.75 | -258.98 | -438.68 | -224.13 | -243.66 |